IDEXX Reports Strong Q1 Results, Raises Full-Year Revenue and EPS Guidance

summarizeSummary

IDEXX Laboratories announced strong first-quarter financial results, exceeding expectations, and subsequently raised its full-year 2026 revenue and EPS guidance, reflecting continued operational strength.

check_boxKey Events

• Strong First Quarter Performance

  Reported Q1 2026 revenue of $1,141 million, an increase of 14% as reported and 11% organically. Diluted EPS reached $3.47, up 17% as reported and 15% on a comparable basis, driven by strong volume growth and innovation.

• Full-Year 2026 Guidance Raised

  Increased 2026 revenue guidance to a range of $4,675 million - $4,760 million, an increase of $42 million at the midpoint. The company also raised its 2026 EPS outlook to $14.45 - $14.90, reflecting an increase of $0.13 per share at the midpoint compared to prior guidance.

• Operational Highlights

  Companion Animal Group (CAG) Diagnostics recurring revenue grew 14% reported and 11% organically, with strong gains in IDEXX VetLab consumables and reference laboratory services. The company also reported $351 million in common stock repurchases during the quarter.

auto_awesomeAnalysis

IDEXX Laboratories delivered robust first-quarter results, exceeding expectations with double-digit revenue and EPS growth. This strong performance, driven by commercial execution and innovation in its Companion Animal Group, has led management to raise its full-year 2026 revenue and EPS guidance. The updated outlook signals continued positive momentum and management's confidence in the company's operational strength and market position, despite the Q1 results being previously reported by news outlets. The raised guidance provides new, material information for investors.